Asterias Biotherapeutics Inc (NYSEAMERICAN:AST)‘s stock had its “buy” rating reiterated by HC Wainwright in a research note issued on Wednesday.

A number of other equities analysts also recently commented on the company. ValuEngine downgraded Asterias Biotherapeutics from a “hold” rating to a “sell” rating in a research note on Monday, September 4th. Zacks Investment Research upgraded Asterias Biotherapeutics from a “hold” rating to a “buy” rating and set a $3.75 target price for the company in a research note on Tuesday, October 10th. One analyst has rated the stock with a sell rating and four have given a buy rating to the company. Asterias Biotherapeutics presently has an average rating of “Buy” and an average target price of $9.19.

Asterias Biotherapeutics (AST) opened at $2.55 on Wednesday. Asterias Biotherapeutics has a 52-week low of $2.00 and a 52-week high of $5.70.

COPYRIGHT VIOLATION NOTICE: This report was first reported by American Banking News and is the property of of American Banking News. If you are accessing this report on another publication, it was illegally stolen and republished in violation of US & international copyright and trademark legislation. The original version of this report can be accessed at https://www.americanbankingnews.com/2017/11/22/asterias-biotherapeutics-inc-ast-stock-rating-reaffirmed-by-hc-wainwright.html.

A number of institutional investors have recently added to or reduced their stakes in the business. State Street Corp raised its position in shares of Asterias Biotherapeutics by 5.5% during the first quarter. State Street Corp now owns 96,218 shares of the biotechnology company’s stock valued at $452,000 after buying an additional 5,000 shares during the last quarter. Oxford Asset Management acquired a new position in shares of Asterias Biotherapeutics during the fourth quarter valued at about $224,000. Thrivent Financial For Lutherans acquired a new position in Asterias Biotherapeutics in the fourth quarter worth about $1,043,000. Sabby Management LLC acquired a new position in Asterias Biotherapeutics in the second quarter worth about $741,000. Finally, Northeast Financial Consultants Inc raised its position in Asterias Biotherapeutics by 1,990.6% in the third quarter. Northeast Financial Consultants Inc now owns 732,265 shares of the biotechnology company’s stock worth $3,105,000 after purchasing an additional 697,239 shares in the last quarter.

About Asterias Biotherapeutics

Asterias Biotherapeutics, Inc is a biotechnology company. The Company is engaged in developing and commercializing therapies in the fields of cell therapy and regenerative medicine. The Company has over two technology platforms. The first is an immunotherapy platform to teach cancer patients’ immune systems to attack their tumors.

Receive News & Ratings for Asterias Biotherapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Asterias Biotherapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.